JP2008517900A - スタフィロコッカス−アウレウスIsdたんぱく質ベースの抗感染薬 - Google Patents

スタフィロコッカス−アウレウスIsdたんぱく質ベースの抗感染薬 Download PDF

Info

Publication number
JP2008517900A
JP2008517900A JP2007537422A JP2007537422A JP2008517900A JP 2008517900 A JP2008517900 A JP 2008517900A JP 2007537422 A JP2007537422 A JP 2007537422A JP 2007537422 A JP2007537422 A JP 2007537422A JP 2008517900 A JP2008517900 A JP 2008517900A
Authority
JP
Japan
Prior art keywords
polypeptide
isd
protein
isda
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007537422A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008517900A5 (https=
Inventor
デイビッド,イー. ハインリッヒ,
クリスティー バーマイレン,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universityof Western Ontario
Original Assignee
Universityof Western Ontario
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universityof Western Ontario filed Critical Universityof Western Ontario
Publication of JP2008517900A publication Critical patent/JP2008517900A/ja
Publication of JP2008517900A5 publication Critical patent/JP2008517900A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2007537422A 2004-10-25 2005-10-25 スタフィロコッカス−アウレウスIsdたんぱく質ベースの抗感染薬 Pending JP2008517900A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62192104P 2004-10-25 2004-10-25
PCT/IB2005/004126 WO2006059247A2 (en) 2004-10-25 2005-10-25 VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC

Publications (2)

Publication Number Publication Date
JP2008517900A true JP2008517900A (ja) 2008-05-29
JP2008517900A5 JP2008517900A5 (https=) 2008-12-18

Family

ID=36565416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007537422A Pending JP2008517900A (ja) 2004-10-25 2005-10-25 スタフィロコッカス−アウレウスIsdたんぱく質ベースの抗感染薬

Country Status (6)

Country Link
EP (1) EP1812066A4 (https=)
JP (1) JP2008517900A (https=)
KR (1) KR20070085457A (https=)
AU (1) AU2005310981A1 (https=)
CA (1) CA2581746A1 (https=)
WO (1) WO2006059247A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2586125T3 (es) 2005-02-14 2016-10-11 Epitopix, Llc Polipéptidos de Staphylococcus aureus y métodos de uso
US20090317421A1 (en) * 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
CA2667788A1 (en) * 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
EP2185190B1 (en) 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
NZ614557A (en) 2009-03-23 2015-03-27 Epitopix Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
ES2784957T3 (es) 2009-04-03 2020-10-02 Univ Chicago Composiciones y métodos relacionados con variantes de la proteína A (SPA)
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP6002128B2 (ja) 2010-07-02 2016-10-05 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago プロテインA(SpA)変種に関連する組成物および方法
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
SG11201507141SA (en) * 2013-03-15 2015-10-29 Techulon Inc Antisense molecules for treatment of staphylococcus aureus infection
US9834768B2 (en) 2014-12-31 2017-12-05 Korea Advanced Institute Of Science And Technology Effective method for specific gene silencing using artificial small RNA
MX2021013833A (es) 2019-05-14 2022-03-17 Univ Chicago Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
WO2021051136A1 (en) 2019-09-13 2021-03-18 The University Of Chicago Methods and compositions for treating staphylococcal infections
CN120943954B (zh) * 2025-10-20 2026-02-06 重庆原伦生物科技有限公司 抗金黄色葡萄球菌IsdB抗体的制备及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102829A2 (en) * 2001-06-15 2002-12-27 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
JP2007502101A (ja) * 2003-07-24 2007-02-08 メルク エンド カムパニー インコーポレーテッド スタフィロコッカス・アウレウスに対して防御免疫応答を誘導するポリペプチド
JP2008513406A (ja) * 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
EP1412379B1 (en) * 2001-08-02 2012-01-25 The University Of Sheffield Vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102829A2 (en) * 2001-06-15 2002-12-27 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
JP2007502101A (ja) * 2003-07-24 2007-02-08 メルク エンド カムパニー インコーポレーテッド スタフィロコッカス・アウレウスに対して防御免疫応答を誘導するポリペプチド
JP2008513406A (ja) * 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物

Also Published As

Publication number Publication date
WO2006059247A2 (en) 2006-06-08
KR20070085457A (ko) 2007-08-27
CA2581746A1 (en) 2006-06-08
EP1812066A2 (en) 2007-08-01
WO2006059247A8 (en) 2007-04-26
AU2005310981A1 (en) 2006-06-08
EP1812066A4 (en) 2010-06-30
WO2006059247A3 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
WO2008152447A2 (en) Staphylococcus aureus specific anti-infectives
JP2008517900A (ja) スタフィロコッカス−アウレウスIsdたんぱく質ベースの抗感染薬
US8067015B2 (en) Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
CN107660211A (zh) 新的对绿脓菌荧光素和绿脓菌螯铁蛋白特异性的蛋白质
US20050220788A1 (en) Use of molecules which interact with the haptoglobin receptor ligand binding
US20080050361A1 (en) Staphylococcus aureas specific anti-infectives
Hughes et al. Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59
DK1784220T3 (en) BACTERIAL OBJECTIVES TO ACHIEVE IRON
US8729013B2 (en) Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
JP2008512108A (ja) スタフィロコッカス−アウレウス−シデロフォアの阻害剤のスクリーニング検定
JPH10113189A (ja) 新規 RNaseP
US20070292873A1 (en) Bacterial iron acquisition targets
US20100129349A1 (en) Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
JPH11235183A (ja) シグナル認識粒子ポリペプチドおよびポリヌクレオチド
JP2001514025A (ja) 新規rnasep
JPH11337548A (ja) 新規DbpB
JP4270466B2 (ja) NADase、SNIおよびSLO遺伝子を含むオペロンから発現するタンパク質の製造方法、それにより得られるタンパク質およびその使用
Xiao et al. Selection and identification of a new adhesion protein of Cryptosporidium parvum from a cDNA library by ribosome display
JP2002525048A (ja) Rnasepポリペプチド
Majhi Cloning of ddi (DNA damage inducible) gene in pfcenv 3\v4 transection vectors and production of recombinant generation of antibodies
EP2053058A1 (en) Attenuation of bacterial virulence
JP2006081413A (ja) 抗真核微生物剤のスクリーニング方法
JP2001513337A (ja) 新規priA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110913